The role of OX40/OX40L in the engraftment of MHC class I or II-disparate T-cell-depleted donor BM grafts
| Group . | TBI . | Day . | No. . | Donor, % (SD) . | Host, % (SD) . |
|---|---|---|---|---|---|
| B6-CD45.1→bm12 | |||||
| Irrelevant mAb | 5.0 | 115 | 15 | 88 (4) | 12 (4) |
| αOX40 mAb | 5.0 | 115 | 15 | 16 (2)* | 87 (2)* |
| αOX40L mAb | 5.0 | 115 | 15 | 97 (1)* | 6 (1) |
| Irrelevant mAb | 4.5 | 120 | 13 | 81 (7) | 20 (6) |
| αOX40L mAb | 4.5 | 120 | 14 | 94 (1)† | 10 (1)† |
| B6-CD45.1→bm1 | |||||
| Irrelevant mAb | 5.0 | 97 | 15 | 88 (6) | 12 (5) |
| αOX40 mAb | 5.0 | 97 | 15 | 68 (9)† | 33 (9)† |
| Irrelevant mAb | 4.5 | 100 | 15 | 79 (8) | 22 (7) |
| αOX40L mAb | 4.5 | 100 | 15 | 65 (10) | 36 (10) |
| Group . | TBI . | Day . | No. . | Donor, % (SD) . | Host, % (SD) . |
|---|---|---|---|---|---|
| B6-CD45.1→bm12 | |||||
| Irrelevant mAb | 5.0 | 115 | 15 | 88 (4) | 12 (4) |
| αOX40 mAb | 5.0 | 115 | 15 | 16 (2)* | 87 (2)* |
| αOX40L mAb | 5.0 | 115 | 15 | 97 (1)* | 6 (1) |
| Irrelevant mAb | 4.5 | 120 | 13 | 81 (7) | 20 (6) |
| αOX40L mAb | 4.5 | 120 | 14 | 94 (1)† | 10 (1)† |
| B6-CD45.1→bm1 | |||||
| Irrelevant mAb | 5.0 | 97 | 15 | 88 (6) | 12 (5) |
| αOX40 mAb | 5.0 | 97 | 15 | 68 (9)† | 33 (9)† |
| Irrelevant mAb | 4.5 | 100 | 15 | 79 (8) | 22 (7) |
| αOX40L mAb | 4.5 | 100 | 15 | 65 (10) | 36 (10) |
B6-CD45.1 recipients (n = 15 per group) were sublethally irradiated with TBI doses, as indicated, on day −1 and then given 0.7 to 1 × 107 TCD BM from bm1 or bm12 donors and either irrelevant IgG, anti-OX40, or anti-OX40L mAb as described in ‘Materials and methods.” On the indicated day after BMT, all surviving recipients were phenotyped to determine the donor or host origin of peripheral blood mononuclear cells. Values shown are mean percentages. The standard deviation of the mean is listed in parentheses.
P ≤ .05 versus irrelevant mAb controls.
.05 < P ≤ .10 versus irrelevant mAb controls.